Found: 3
Select item for more details and to access through your institution.
CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models.
- Published in:
- Science Translational Medicine, 2022, v. 14, n. 670, p. 1, doi. 10.1126/scitranslmed.abn1082
- By:
- Publication type:
- Article
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy.
- Published in:
- Science Translational Medicine, 2020, v. 12, n. 549, p. 1, doi. 10.1126/scitranslmed.aba2325
- By:
- Publication type:
- Article
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
- Published in:
- Science Translational Medicine, 2020, v. 12, n. 525, p. 1, doi. 10.1126/scitranslmed.aaw7888
- By:
- Publication type:
- Article